Invitation to Participate in STOP-PC Clinical Trial

March 4, 2024

AGOURA HILLS, Calif., March 04, 2024 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) invites participation in our STOP-PC clinical trial which is now open for recruitment. Additional information can be obtained at www.stop-pc.com. An explainer video is available at https://www.youtube.com/watch?v=C4ZsE3fulIU.

Related news for (OTLC)

Product Manager Scott Myers to Present at 2nd Global Summit on Artificial Intelligence
ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY
ONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETING
ONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETING
Linkage of Cancer and Lupus in Gliomas Patients

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.

Invitation to Participate in STOP-PC Clinical Trial

Related news for (OTLC)

Follow Us on Social Media

Sign Up for Our Newsletter

Related news for (OTLC)

A RUM and AI, Please

Midday Market Dispatch- From Eco‑Boards to AI Batteries

Market Spotlight: APLD Powers AI, KDK Rolls Out, FICO Reinvents Scoring—And VENU Amplifies the Concert Economy

Kraig Labs Unlocks Spider Silk at Scale, Solving a Historical Problem for Nature’s Toughest Fiber

VENU Leads the Intimate Concert Trend with Boutique Venue Solutions

Follow Us on Social Media

Sign Up for Our Newsletter